SCHEMBL457991

SCHEMBL457991

CC(=O)Oc1ccccc1Nc1c(Cl)cccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 7/20 0.51
PTGS2 P35354 5/20 0.50
TTR P02766 3/20 0.50
PTGS1 P23219 3/20 0.50
AKR1B10 O60218 1/20 0.50
UGT1A9 O60656 1/20 0.50
TRPA1 O75762 1/20 0.50
ABCB11 O95342 1/20 0.50
MT-CO2 P00403 1/20 0.50
ALB P02768 1/20 0.50
UGT1A6 P19224 1/20 0.50
UGT1A1 P22309 1/20 0.50
CXCR1 P25024 1/20 0.50
ADRA1A P35348 1/20 0.50
AGTR2 P50052 1/20 0.50
NR1I3 Q14994 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
NR1H4 Q96RI1 1/20 0.50
UGT1A7 Q9HAW7 1/20 0.50
UGT1A10 Q9HAW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9618521 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL8053100 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL29598223 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL9618518 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
Potassium SCHEMBL8053105 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
Rubidium SCHEMBL9618522 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL1961600 0.98 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
Diethylamine SCHEMBL9790067 0.92 CXCL8 (0.47) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL10412874 0.91 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL10413114 0.91 CXCL8 (0.50) CXCL8PTGS2TTRPTGS1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170826-B1 PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES TECHFIELDS INC (US) 2022-04-27 EP claimed
EP-2598475-A1 PROCESS FOR THE SYNTHESIS OF DICLOFENAC CHOLINE SALT FARMAKA S.r.l. (IT) 2013-06-05 EP claimed
WO-2013008104-A1 PROCESS FOR THE SYNTHESIS OF DICLOFENAC CHOLINE SALT FARMAKA S.R.L. (IT) 2013-01-17 WO claimed
US-8153689-B2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes NABRIVA THERAPEUTICS AG (AT) 2012-04-10 US claimed
US-20120029072-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG 2012-02-02 US claimed
CN-1747731-A Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders ALTANA PHARMA AG (DE) 2006-03-15 CN claimed
EP-0946170-B1 DICLOFENAC FOR THE TREATMENT OF VASCULOPATHIES EXOCELL INC (US) 2005-10-12 EP claimed
CN-1625411-A Combination of a NSAID and a PDE-4 inhibitor ALTANA PHARMA AG (DE) 2005-06-08 CN claimed
US-6710086-B1 CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT MEDINOX, INC. 2004-03-23 US claimed
WO-2003068203-A1 USE OF A COMBINATION OF A NON-STEROIDAL ANTI-INFLAMMATORY AGENT AND GUAIFENESIN FOR THE TREATMENT OF ACUTE PAIN ZENTIVA, A.S. (CZ) 2003-08-21 WO claimed
JP-4312561-A None JP disclosed
JP-55013227-A None JP disclosed
JP-4091061-A None JP disclosed
JP-54145627-A None JP disclosed
JP-63041475-A None JP disclosed
EP-0041576-A1 1-(2,6-DICHLOROPHENYL)-2-QUINOLINONEIMINE-3-CARBOXYLIC ACID, PRODUCTION PROCESS THEREFOR AND ANTI-INFLAMMATORY AND ANALGESIC COMPOSITION CONTAINING THE COMPOUND DAITO KOEKI KABUSHIKI KAISHA (JP) 1981-12-16 EP disclosed
US-4189595-A [N-benzyl-o-(2,6-dichloroanilino)phenyl]acetic acid derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1980-02-19 US disclosed
JP-S5522628-A GLYCIDATE AND ITS PREPARATION DAITO KOEKI KK 1980-02-18 JP disclosed
JP-S5513227-A PRODUCTION OF 2-(2,6-DICHLOROANILINO)PHENYL ACETIC ACID IKEDA MOHANDOU:KK 1980-01-30 JP disclosed
JP-S54145627-A PREPARATION OF 2-(2,6-DICHLOROANILINO)PHENYL ACETIC ACID NISSAN CHEM IND LTD 1979-11-14 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029072-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, FABP6, PLEC CXCL8 357/4885PTGS2 407/4885TTR 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.